The Oncology Podcast

Send us Fan Mail
In this episode of The Oncology Journal Club, the team cover one of the most talked-about pancreatic cancer papers of the year, unpacking the promising early results for daraxonrasib in previously treated RAS-mutated pancreatic cancer and the science behind new RAS(ON) therapeutics. 
The team also discuss a fascinating phase II study of single-cycle neoadjuvant pembrolizumab in MMR-deficient colon cancer, new recommendations from the Prostate Cancer Working Group 4 and why the terminology we use in prostate cancer matters.
Along the way, there’s discussion of Bob Marley’s acral melanoma, multidisciplinary lung cancer meetings, androgen receptor-positive TNBC, HER2-mutant lung cancer and whether oxybutynin could help men experiencing androgen deprivation-related hot flushes.
The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network
Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information.

Send us Fan Mail
Proudly Produced by The Oncology Network
Professor Craig Underhill and Rachael Babin break down the key oncology changes from the May 2026 PBS update.
This month we run through 3 fresh PBS listings that affect Australian oncology and haematology practice, from fruquintinib, a late-line colorectal cancer treatment, through to new haematology options.  
Follow The PBS Update for regular discussions of PBS listings and oncology policy changes affecting Australian healthcare professionals.
Visit the Show Notes for links to the updates discussed in this episode and to send us audio feedback or questions for future episodes.

Send us Fan Mail
In this episode of The Oncology Journal Club, the team weigh promising trial signals against the level of evidence needed to change clinical practice. From perioperative cholangiocarcinoma to molecular matching and chrono-oncology, the focus stays on a key question: what meaningfully improves outcomes for patients?
What’s covered
 NeoGOLP trial in high-risk resectable iCCA: improved event-free survival; overall survival still immature 
 MoST programme: molecular matching and survival associations when therapies align with biomarkers 
 Genomic therapy matching in clinical decision-making 
 Chrono-oncology: does treatment timing influence outcomes? 
 CHOPIN phase II uveal melanoma trial: combination therapy signals and feasibility 
 ASCO living guideline updates across lung, gastro-oesophageal and thyroid cancers 
The Oncology Journal Club Podcast hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology Network
Visit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information.

Send us Fan Mail
Proudly Produced by The Oncology Network
Professor Craig Underhill and Rachael Babin break down the key oncology changes from the April 2026 PBS update.
This month we run through six fresh PBS listings and policy changes that affect Australian oncology and haematology practice, from ROS1-positive non small cell lung cancer to perioperative immunotherapy and late-line blood cancer options. 
We focus on who benefits, what the key trial signals are and what clinicians need to monitor so access translates into safe, real-world outcomes. 
Repotrectinib listed for ROS1-positive NSCLC, including activity after prior TKIs and in resistant mutations, plus monitoring for dizziness and pneumonitis 
Durvalumab listed for muscle-invasive bladder cancer using the Niagara perioperative regimen, balancing survival gains with immune-related toxicity 
Three new pembrolizumab listings across cervical cancer, adjuvant renal cell carcinoma and perioperative head and neck cancer, with discussion of endpoints and eligibility 
Haematology additions including a BCMA bispecific for relapsed myeloma, an oral kinase inhibitor for higher-risk myelofibrosis and mogamulizumab for cutaneous T-cell lymphoma 
PBS price cuts via generics and biosimilars, plus expanded supervised prescribing for some medicines by nurse practitioners
Follow The PBS Update for regular discussions of PBS listings and oncology policy changes affecting Australian healthcare professionals.
Visit the Show Notes for links to the updates discussed in this episode and to send us audio feedback or questions for future episodes.

Send us Fan Mail
Australia’s PBS has introduced it’s first pan-tumour reimbursement listing for the immunotherapy combination nivolumab plus ipilimumab. In this inaugural episode of PBS Update, Professor Craig Underhill and Rachael Babin break down the key oncology changes from the March 2026 PBS update, including new listings for toripalimab and cabozantinib.
Follow PBS Update for regular discussions on PBS listings and oncology policy changes affecting Australian healthcare professionals.
Visit the Show Notes for links to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.